Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Department of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Kouto, Shingu-cho, Tatsuno, Hyogo, 679-5165, Japan.
Radiat Oncol. 2021 Jan 6;16(1):3. doi: 10.1186/s13014-020-01731-z.
Particle radiotherapy has increasingly gained acceptance for locally advanced pancreatic cancers owing to superior tumor conformity and dosimetry compared to conventional photon radiotherapy. However, the close proximity of the pancreas to the stomach and duodenum leads to radiation-induced gastrointestinal toxicities, which hinder the delivery of curative doses to the tumor. To overcome this problem, a surgical spacer was placed between the tumor and gastrointestinal tract, and subsequent proton radiotherapy was performed in this study.
Data from 9 patients who underwent surgical spacer placement and subsequent proton radiotherapy were analyzed. The safety and feasibility of the spacer placement surgery were evaluated; the impact of the spacer on dosimetry was also assessed using dose volume histogram (DVH) analyses, before and after surgical spacer placement.
Surgical spacer placement and subsequent proton radiotherapy were successfully completed in all cases. Surgical spacer placement significantly improved the dose intensity covering 95%, mean, and minimum doses for the gross tumor volume, and the clinical and planning target volume based on the DVH, while respecting the dose constraints of the gastrointestinal tract. Based on the Common Terminology Criteria for Adverse Events, two patients (22.2%) developed gastrointestinal ulcer (Grade 2) at 1 and 35 months, and one patient (11.1%) developed gastric perforation (Grade 4) at 4 months after proton radiotherapy.
Surgical spacer placement in the locally advanced pancreatic body and tail cancers is relatively safe and technically feasible. Comparing radiation plans, surgical spacer placement seems to improve the dose distribution in the locally advanced pancreatic body and tail cancers, which are close to the gastrointestinal tract.
与传统光子放疗相比,粒子放疗由于肿瘤适形度和剂量分布更好,越来越多地被用于局部晚期胰腺癌。然而,胰腺与胃和十二指肠毗邻,导致放射性胃肠道毒性,这阻碍了对肿瘤的根治性剂量的输送。为了解决这个问题,在肿瘤和胃肠道之间放置了一个外科间隔器,随后在本研究中进行了质子放疗。
分析了 9 名接受外科间隔器放置和随后质子放疗的患者的数据。评估了间隔器放置手术的安全性和可行性;还通过剂量体积直方图(DVH)分析,评估了间隔器对剂量学的影响,包括手术前后。
所有病例均成功完成外科间隔器放置和随后的质子放疗。外科间隔器放置显著提高了 95%、平均和最小剂量覆盖肿瘤总体积、临床和计划靶区的剂量强度,同时尊重胃肠道的剂量限制。根据常见不良事件术语标准,2 名患者(22.2%)在质子放疗后 1 个月和 35 个月分别出现胃肠道溃疡(2 级),1 名患者(11.1%)在质子放疗后 4 个月出现胃穿孔(4 级)。
局部晚期胰体尾癌的外科间隔器放置相对安全且技术上可行。比较放疗计划,外科间隔器放置似乎改善了靠近胃肠道的局部晚期胰体尾癌的剂量分布。